Bio Technology General - BTGC Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Bio Technology General - BTGC

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Dave O. who wrote (1979)	1/19/2000 5:58:00 PM
From: Jim Oravetz	Read Replies (2) of 2028

Genentech to Appeal Bio-Technology General Ruling The motion to preserve the injunction asking for a full review will be filed with the Federal Circuit Court of Appeals in Washington D.C. This is the same court that previously reviewed and affirmed the injunction following a two-week hearing conducted by another district court judge in 1995. The patent that is being disputed is U.S. patent No. 4,601,980 granted in July 1985. This patent expires in July 2003. The patent pertains to the methods for making recombinant human growth hormone. And now for a little more PLUS news: Anthony P. Shimkin, an analyst with Wedbush Morgan Securities in Los Angeles, which tracks Bio-Tech stock, said last week that a verdict in Bio-Tech's favor could significantly boost Bio-Tech's sales of Bio-Tropin, its human growth hormone drug. Bio-Tech sells $17.1 million worth of Bio-Tropin annually, a Bio-Tech spokeswoman said. "You're looking at, conservatively, double the sales,' Shimkin said. Jim

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next